Evidence map›Paper›PMID 37546220›Full record

ArticleRSC advances2023

The synthesis and development of poly(ε-caprolactone) conjugated polyoxyethylene sorbitan oleate-based micelles for curcumin drug release: an

Nasim Shadmani, Sepehr Gohari, Azin Kadkhodamanesh, Parivash Ghaderinia, Maryam Hassani, Motahare Sharifyrad

Abstract read
In one paragraph

Article in RSC advances, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Development and evaluation of a PLGA/TiOJournal of advanced periodontology & implant dentistry · 2026
    Article
  2. Article
  3. Curcumin nanoparticles in heat stroke management.Journal of nanobiotechnology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nasim ShadmaniTrita Nanomedicine Research & Technology Development Center (TNRTC) Zanjan Health Technology Park Zanjan Iran.
Sepehr GohariStudent Research Center, School of Medicine, Zanjan University of Medical Sciences Zanjan Iran.ORCID https://orcid.org/0000-0002-2177-8124
Azin KadkhodamaneshSchool of Pharmacy, Shahid Beheshti University of Medical Sciences Tehran Iran.
Parivash GhaderiniaResearch and Technology Development Center of the Motahar Zist Gostar, Islamic Azad University Zanjan Branch Zanjan Iran 45156-58145 M.rad4294@gmail.com +98 9191815229.
Maryam HassaniDepartment of Pharmaceutical Biomaterials, Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences Tehran Iran.
Motahare SharifyradResearch and Technology Development Center of the Motahar Zist Gostar, Islamic Azad University Zanjan Branch Zanjan Iran 45156-58145 M.rad4294@gmail.com +98 9191815229.ORCID https://orcid.org/0000-0001-9016-1630

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundit is now known that curcumin (Cur) has a broad range of biological properties; however, photosensitivity, as well as low bioavailability and short half-life, have limited its clinical application. To overcome these problems the synthesis of poly(ε-caprolactone)-Tween 80 (PCL-T) copolymers was performed.

methodsthe copolymers of PCL-T were created using the solvent evaporation/extraction technique. Then Cur was loaded in PCL-T micelles (PCL-T-M) by a self-assembly method. The characterization of copolymer and micelles was assessed by gel permeation chromatography (GPC), Fourier transform infrared spectroscopy (FT-IR), proton nuclear magnetic resonance spectroscopy (

resultsTEM analysis showed monodispersed and spherical shapes with a size of about 90 nm. Cur was released from PCL-T-M at pH 7.4 (45%) and 5.5 (90%) during 6 days. After 24 and 48 h, the IC50 of the free Cur, PCL-T-M, and Cur-loaded PCL-T-M on MCF-7 cells were 80.86 and 54.45 μg mL

conclusionthis study showed that, in the same concentration, the effectiveness of the Cur-loaded PCL-T-M is more than the free Cur, and the nano-system has been able to overcome delivery obstacles of Cur drug. Thus, PCL-T-M can be a candidate as a drug carrier for the delivery of Cur and future therapeutic investigations on breast cancer.

Identifiers

PMID37546220
PMCPMC10401665

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.